A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Emixustat (Primary)
- Indications Stargardt disease
- Focus Pharmacodynamics
- Sponsors Acucela
- 17 Jan 2018 Status changed from recruiting to completed.
- 26 Jan 2017 Status changed from planning to recruiting, as per an Acucela media release.
- 13 Jun 2016 According to an Acucela Inc. media release, the company plans to initiate this trial by the end of 2016.